InvestorsObserver
Sign Up Login

JNCE Jounce Therapeutics Inc

$1.51 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

JNCE Stock Analysis Overview

What this means: InvestorsObserver gives Jounce Therapeutics Inc (JNCE) an overall rank of 49, which is below average. Jounce Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 49 means that 51% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

JNCE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

JNCE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

JNCE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

JNCE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

JNCE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

JNCE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

JNCE Stock Analysis Overview

What this means: InvestorsObserver gives Jounce Therapeutics Inc (JNCE) an overall rank of 49, which is below average. Jounce Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 49 means that 51% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full JNCE report

JNCE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

JNCE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

JNCE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

JNCE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

JNCE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

JNCE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Jounce Therapeutics Inc (JNCE) Analyst Forecast

JNCE Price, Volume, Earnings, and Dividend Date

  • Last Price $1.51
  • Previous Close $1.51
  • Change $0.00
  • Open $1.50
  • Volume 919,749
  • Avg. Volume (100-day) 2,134,381
  • Market Cap 78,731,818
  • Days Range 1.455 - 1.52
  • 52-week Range 0.58 - 7.94
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 10.8
  • EPS —
  • Earnings Date 03/29/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.702
  • PEG Ratio —

Jounce Therapeutics Inc (JNCE) Company Description

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Jounce Therapeutics Inc (JNCE) Stock Chart

View Interactive JNCE chart

My Watchlists

Top Stocks in Biotechnology